OBJECTIVE: Elevated macrophage migration inhibitory factor (MIF) has been implicated as a causal mechanism in a number of disease conditions including cardiovascular disease (CVD), diabetes, and cancer. Excess body fat is associated with an increased risk of numerous health conditions including CVD, diabetes, and cancer. To our knowledge, the association between MIF and obesity status and the effect of weight loss on serum MIF concentrations have not been reported. In this study, we examined the effects of participation in a behavior-based weight loss program on MIF concentrations in obese individuals. 
Introduction
Although macrophage migration inhibitory factor (MIF) is one of the earliest discovered cytokines, it is also one of the least understood. However, the physiological role, locations of production and secretion, and potential risks associated with elevated plasma MIF concentrations have been the focus of recent investigations. For example, MIF plays a role in atherosclerotic plaque formation, has powerful proinflammatory effects, and has been postulated to be a primary modulator of insulin release of the pancreas. [1] [2] [3] [4] [5] [6] [7] Thus, MIF may play an important role in the development of cardiovascular disease (CVD) and/or diabetes. Since MIF is a potent regulator of cell proliferation and differentiation and is thought to play a role in tumor growth and neovascularization, MIF may also have a role in the development of cancer. 1, 8, 9 MIF is produced and released by a number of tissues throughout the body, and in rodents, MIF is expressed and released from adipocites. 10 Excess body fat is associated with an increased risk of numerous morbidities including CVD, diabetes, and some cancers. 11 However, the pathophysiological mechanisms whereby increased body weight promotes these health conditions remains largely unexplained. To our knowledge, the association between MIF and obesity status and the effect of weight loss on serum MIF concentrations has not been reported. In this study, we examined the effects of participation in a behaviorally based weight loss program on MIF concentrations in obese individuals.
Methods
Study participants were 71 men and women enrolled in The Cooper Institute Weight Management Program. This fee-forservice program is a behaviorally based weight loss program that focuses on teaching participants the required skills to increase daily physical activity and reduce caloric intake. The current analyses included only participants with complete data at baseline and either 6-or 12-month follow-up data. Participants provided informed consent to participate in the weight management program and to use their data for research purposes. The Cooper Institute IRB annually reviewed and approved the study protocol.
Study design
All participants received a baseline clinical examination as part of the program. This examination consisted of a physical examination by a physician, blood chemistry analyses, resting blood pressure, and anthropometry. We used an extensive questionnaire to obtain demographic characteristics, health history, family medical history, and a health habit inventory. Blood pressure was measured following the American Heart Association protocol. 12 Weight was measured on an electronic scale designed for heavier weights (Siemens Medical Solutions, Malvern, PA, USA) and height was measured using a standard stadiometer. Body mass index (BMI) was calculated as weight in kilograms, divided by height in meters squared. All participants fasted at least 8 h prior to blood chemistry analysis. With the exception of insulin and MIF, commercial laboratories (Lab Corporation of America, Burlington, NC, USA and Cooper Clinic Laboratory Services, Dallas, TX, USA) performed the analyses. High-sensitivity C-reactive protein (CRP) was measured with a Prospect nephelometer (Dade Division of Baxter Healthcare Corporation, DE, USA).
MIF and insulin measurements
Plasma MIF concentration was determined using the ChemikineTM Human macrophage inhibitory factor EIA kit (Chemicon International, Inc., Temecula, CA, USA) according to the manufacturer's instructions. Samples (in duplicate) were diluted in reaction buffer if the concentration was determined to be greater than the highest concentration of the standard curve. The optical density at 450 nm (reference 630 nm) was read on a MRX Revelation microtiter plate reader (Dynex Technologies, Chantilly, VA, USA) within 30 min of completion of the assay. No significant hemolysis was noted in any of the samples used in this study. According to the manufacturer of the MIF EIA kits, the intra-assay variation of the MIF ELISA is 76.8% (interassay variation: 77.4%). The intra-assay variation of the Insulin ELISA is reported to be 72.8-4.0% (interassay variation: 72.6-3.6%). Insulin sensitivity was assessed with the homeostasis model (HOMA). Insulin resistance (HOMA-IR) was quantified as fasting plasma glucose (mmol/l) Â fasting insulin (mU/ml) divided by 25. Insulin secretion or pancreatic b-cell function (HOMA-b) was quantified as (fasting insulin (mU/ml) Â 20)/ (fasting plasma glucose (mmol/l)-3.5).
Statistical analyses
The distribution of MIF was skewed to the right (Figure 1 ). Sample-specific MIF tertiles were calculated for categorical analysis. For the descriptive variables, we computed the arithmetic mean and standard deviation of each variable (prevalence of dichotomous variables) by MIF tertiles. To examine the risk factor profiles across levels of MIF, general linear models were used to examine differences in mean levels (geometric men for non-normally distributed variables) of the risk factor variables across MIF tertiles with adjustment for the potential confounding effects of age, gender, and hormone replacement therapy (HRT) use. As MIF has been linked to glucose metabolism, we compared the baseline prevalence of high fasting glucose (Z100 mg/dl), high insulin concentrations (417.0 mU/ml), high HOMA-IR (44.7), and low HOMA-b (o75) across MIF tertiles with adjustment for age, gender, and HRT use. The fasting glucose cut-point of 100 mg/dl is derived from the current ADA guidelines for identifying pre-diabetes and because there are no standard cut-points for defining high insulin, high HOMA-IR, and low HOMA-b, we used the highest (or lowest) quartile from our population to define the cutpoints. Differences between baseline and follow-up descriptive and risk factor data were examined using paired t-tests. Differences between baseline and follow-up group MIF values were assessed using the Wilcoxon rank-sum test. We calculated the prevalence of individuals at baseline and 
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To examine the changes in measures of glucose metabolism in individuals who had large decreases in MIF, we categorized the study sample into those who reduced MIF by more than 15 ng/ml and those who did not. Differences in baseline and follow-up values of fasting glucose, insulin concentrations, HOMA-IR, and HOMA-b were calculated using general linear regression models with adjustment for baseline age, gender, and HRT use with categorization based on change in MIF.
For all statistical tests, the a level adopted for significance was a two-tailed Pr0.05. Statistical analysis was performed with SAS version 8.2. Table 1 presents the weight loss program participants, characteristics and clinical variables by tertiles of MIF. There were no significant differences for any of the descriptive variables, including anthropometric, across the MIF tertiles. Figure 2 depicts age-adjusted mean MIF for men, women not using HRT, and women using HRT. Women using HRT had higher MIF levels than women not using HRT (P ¼ 0.01). Table 2 summarizes the risk factor data across MIF tertiles with adjustment for age, gender, and HRT use. There was no difference in lipid levels, CRP, or blood pressure according to category of MIF. The adjusted mean HOMA-b in the highest MIF tertile was lower than the adjusted mean HOMA-b in the lowest MIF tertile. In examining the prevalence of glucose metabolism abnormalities, although there were no statistically significant trends, the lowest MIF tertile had a high prevalence of glucose intolerance and elevated insulin, suggesting a high prevalence of insulin resistance. In contrast, the highest MIF tertile also had glucose intolerance but this group had a high prevalence of low HOMA-b, which is associated with b-cell dysfunction. However, given the lack of statistical significance and small cell sizes, these results should be interpreted with caution.
Results

Participants in the weight
Changes in body mass and clinical risk factors subsequent to the weight management program are shown in Table 3 . Average weight loss was 14.4 kg (Po0.001) and the majority of clinical risk factors were significantly improved at followup.
The participants' data for plasma MIF concentrations at baseline and follow-up are presented in Figure 3 MIF and weight loss TS Church et al Table 4 compares changes in measures of glucose metabolism with categorization based on magnitude of change in MIF. Individuals with large reductions in MIF (oÀ15 ng/ml) had a decrease in mean fasting glucose (P ¼ 0.03), and an increase in HOMA-b (P ¼ 0.058) with no concurrent change in HOMA-IR (P ¼ 0.62). In contrast, the group of participants that did not have a large decrease in MIF had no change in mean fasting glucose (P ¼ 0.23) nor HOMA-b (P ¼ 0.10), but had reductions in plasma insulin (P ¼ 0.005) and HOMA-IR (P ¼ 0.002). Additionally, there was a significant difference in insulin, HOMA-IR, and HOMA-b when comparing the between group changes.
Medication record review in participants who demonstrated a large decrease in MIF suggested the changes in MIF were not the result of changes in medication. 
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Discussion
The primary findings in this study are (1) plasma MIF concentrations are elevated in obese but otherwise healthy individuals; however, this elevation in MIF was not uniform within our population; (2) in obese individuals with elevated MIF concentrations, participation in a behaviorally based weight management program resulted in substantial reduction in MIF; and (3) elevated plasma MIF concentrations appear to be associated with b-cell dysfunction, and individuals who had improvements in MIF also had improvements in b-cell function.
MIF and associations
The mean plasma MIF concentrations of our reference group were similar to those found in other studies. 2, 9, [13] [14] [15] [16] Although our study population had considerably higher mean MIF values than those reported in other studies and our small reference group, most of the weight management participants did not have a markedly elevated plasma MIF concentration. Thus, the elevated mean group MIF in the weight management group was due to small portion of the total sample, as supported by the distribution of MIF (Figure 1) . A question remains as to why some obese individuals have an elevated MIF while others do not. We did not find weight, waist girth, CRP, or any of the CVD risk factors to be associated with elevated MIF. In contrast, we did find HRT use to be associated with increased risk of having elevated plasma MIF concentration.
MIF and disease
Elevated levels of MIF have been suggested as a contributor to a number of disease processes including diabetes, heart disease, and cancer. Previous research has shown that MIF is a potent regulator of cell proliferation and differentiation, can promote tumor growth and neovascularization, and suppresses the action of the tumor suppression gene p53. 8 Our report provides further evidence that in select individuals obesity substantially elevates MIF, possibly providing a potential mechanism for previous epidemiological reports linking excess body weight with increased risk for cancer.
11
Although there are numerous studies relating increased body weight to cancer incidence and mortality, there remain few plausible biological mechanisms to explain this association. Our findings, although in need of confirmation, suggest that elevations in MIF may be a link between excess body weight and cancer.
Our study population lost a significant amount of weight (À11.4%) during the weight loss intervention and showed great improvements in the CVD risk factors, as well as demonstrating a significant decrease in plasma MIF concentrations. Despite this weight loss, the group still fell into the class II obese category at follow-up. These findings parallel those of others who have reported that overweight and obese individuals can improve their risk factor profiles substantially through participation in a weight management program despite not achieving a BMI o25.
11 Thus, the benefits of participation in a weight loss program are not due to the complete normalization of weight. Whether the physiological mechanisms responsible for the improvement in MIF are due to reduced body fat, changes in diet, or physical activity, or participants being in negative caloric balance cannot be determined from this study and should be the focus of future work. compared to diabetes-free individuals, but found no association between fasting glucose or hemoglobin A1c with MIF. However, both these reports were preliminary in nature published as letters to the editor; therefore, paucity in literature exists examining the association between MIF and body composition in vivo.
MIF and glucose metabolism
In vitro studies have provided further evidence that MIF may play a role in glucose metabolism both in the periphery expressed by b cells and the production of MIF is regulated by glucose in a time-and concentration-dependent manner. Further they found that MIF regulates insulin release in an autocrine fashion. The authors speculated that a progressive decrease in MIF action within the islets of Langerhans may contribute to the b-cell dysfunction and the diminished insulin release associated with type 2 diabetes. Our finding that elevated MIF is associated with reduced b-cell function in individuals with elevated fasting glucose levels provides evidence to support the hypothesis that reduced MIF action in the islet cells may be responsible for the decreased b-cell function in a subset of individuals with pre-diabetes. This is further supported by the finding that individuals who had a substantial decrease in MIF also had an increase in plasma insulin compared to individuals who had minimal change in MIF. It is conceivable that in the presence of elevated plasma glucose, elevated MIF is a marker for b-cell dysfunction, and improvements in MIF may be a sign of improving b-cell function. However, given the small size of some of the cells in the subanalysis paired with the diverse nature of the population, these results should be interpreted with caution and serve as the foundation for future, large, more tightly controlled studies.
There are a number of weaknesses in the current study design that deserve mention. First, the population was a sample of convenience, not a randomized trial with a nonintervention obese control group. Further, complete and detailed dietary records were not available to examine the association between dietary quality and plasma MIF concentrations or changes in diet and changes in circulating MIF levels. The population consisted primarily of Caucasians limiting the generalizability of the results. Our study also has a number of strengths including detailed medical examinations including medication records. Our study population was morbidly obese at baseline and the intervention was clearly successful as evidenced both by the group weight loss and the improvement in CVD risk factors. The use of a behaviorally based intervention eliminates many of the confounding issues that may be associated with a surgery-or medication-based weight loss program.
Although MIF is associated with acute illnesses, it is unlikely that this could explain our findings. Specifically, all participants reported no acute illness at baseline. Furthermore, if the very high circulating MIF values found at baseline were due to acute illness, similar elevations in plasma MIF concentrations due to acute illness would have been observed at the follow-up visits and they were not. Lastly, all participants had a white blood cell count at baseline o12 000/ml, except one participant who had a 13 200/ml suggesting there were no individuals with a significant acute illness.
Conclusions
Circulating MIF concentrations are elevated in obese but otherwise healthy individuals; however, this elevation in MIF is not uniform across individuals. In obese individuals with elevated circulating MIF concentrations, participation in a physical activity and dietary focused weight management program resulted in substantial reduction in MIF.
